The therapeutic effects of pegasys in chronic hepatitis B patients with low-level ALT / 中华实验和临床病毒学杂志
Chinese Journal of Experimental and Clinical Virology
;
(6): 196-198, 2013.
Article
in Chinese
| WPRIM
| ID: wpr-318067
ABSTRACT
<p><b>OBJECTIVE</b>To observe the therapeutic effects of Pegasys (pegylated interferon alpha-2a) in chronic hepatitis B (CHB) patients with low-level alanine transaminase (ALT) < 2 x upper limit of normal (ULN).</p><p><b>METHODS</b>One hundred and seven CHB patients were randomized enrolled including 52 with ALT < 2 x ULN and liver tissues inflammation activity > or = G2 as observational group and 55 with ALT > 2 x ULN as control group. All the enrolled patients received pegasys treatment for 48 weeks and the responses between two groups were compared. Measurement data were analyzed using t test and numeration data were analyzed using chi square test.</p><p><b>RESULTS</b>The reductions of HBV DNA in observational group at different time points were all less than control group (all P < 0.05). At the end of treatment, the HBV DNA negative rate, HBeAg seroconversion rate and HBsAg loss rate in the observational group were 51.9%, 48.8% and 1.9% , respectively, which were all lower than control group (67.3% , 66.7% and 7. 3% , respectivley) ( all P <0. 05). The ALT normalization rates of two groups were 75% and 76.4% (P > 0. 05).</p><p><b>CONCLUSION</b>Pegasys is efficient for CHB patients with ALT < 2 x ULN and liver tissues inflammation activity > or = G2, while it is still inferior to those with ALT > 2 x ULN.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Polyethylene Glycols
/
Virology
/
Blood
/
Recombinant Proteins
/
DNA, Viral
/
Interferon-alpha
/
Hepatitis B, Chronic
/
Therapeutic Uses
/
Alanine Transaminase
Type of study:
Controlled clinical trial
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Experimental and Clinical Virology
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS